Global Human Papillomavirus Vaccine (Types 16, 18) Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global Human Papillomavirus Vaccine (Types 16, 18) market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.

Human papillomavirus vaccine (16, 18 types) is a vaccine that can prevent 16, 18 types of human papillomavirus infection. Prophylactic HPV vaccination can effectively reduce 16, 18 types of human papillomavirus infection and related clinical diseases. Inoculation of human papillomavirus vaccines (types 16 and 18) can stimulate the body to produce neutralizing antibodies. When human papillomavirus invades the human body, the neutralizing antibodies can recognize the virus and bind to it, clear the virus through neutralization, and prevent organ failure. Neck cancer, penile cancer, vulvar cancer, oropharyngeal cancer, reproductive Shen and other diseases caused by human papillomavirus infection.

Human papillomavirus vaccine (types 16, 18) is a preventive vaccine that can effectively prevent HPV infection, thereby preventing cervical cancer and other HPV-related cancers. The prevention and treatment of cervical cancer and other HPV-related cancers have undergone major advances due to the development of human papillomavirus vaccines (types 16, 18). The development of human papillomavirus vaccines (types 16, 18) has received global attention and many countries have included it in their national immunization programmes. Over the past few years, the human papillomavirus vaccine (types 16, 18) has achieved great success, and the incidence of cervical cancer and other HPV-related cancers has decreased significantly worldwide. As the HPV vaccine becomes more widely available, its prospects are very promising. Global HPV vaccination rates are expected to increase further and the incidence of cervical cancer and other HPV-related cancers to continue to decline in the coming years. In addition, the development of human papillomavirus vaccines (types 16, 18) will bring additional social and economic benefits, including reducing medical expenditures and improving public health.

This report is a detailed and comprehensive analysis for global Human Papillomavirus Vaccine (Types 16, 18) market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Human Papillomavirus Vaccine (Types 16, 18) market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Human Papillomavirus Vaccine (Types 16, 18) market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Human Papillomavirus Vaccine (Types 16, 18) market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Human Papillomavirus Vaccine (Types 16, 18) market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Human Papillomavirus Vaccine (Types 16, 18)

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Human Papillomavirus Vaccine (Types 16, 18) market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GlaxoSmithKline, Merck & Co., Inc., Serum Institute of India, INNOVAX, ZSSW, HUMANWELL HEALTHCARE, WALVAX, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Human Papillomavirus Vaccine (Types 16, 18) market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

HPV16

HPV18

Market segment by Application

9-26 Years Old

26-45 Years Old

Major players covered

GlaxoSmithKline

Merck & Co., Inc.

Serum Institute of India

INNOVAX

ZSSW

HUMANWELL HEALTHCARE

WALVAX

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Human Papillomavirus Vaccine (Types 16, 18) product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Human Papillomavirus Vaccine (Types 16, 18), with price, sales quantity, revenue, and global market share of Human Papillomavirus Vaccine (Types 16, 18) from 2020 to 2025.

Chapter 3, the Human Papillomavirus Vaccine (Types 16, 18) competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Human Papillomavirus Vaccine (Types 16, 18) breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Human Papillomavirus Vaccine (Types 16, 18) market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Human Papillomavirus Vaccine (Types 16, 18).

Chapter 14 and 15, to describe Human Papillomavirus Vaccine (Types 16, 18) sales channel, distributors, customers, research findings and conclusion.